Eric Blasius Risser
Net Worth

Last updated:

What is Eric Blasius Risser net worth?

The estimated net worth of Mr. Eric Blasius Risser is at least $7,704,318 as of 4 Mar 2024. He owns shares worth $58,739 as insider, has earned $936,569 from insider trading and has received compensation worth at least $6,709,010 in MacroGenics, Inc..

What is the salary of Eric Blasius Risser?

Mr. Eric Blasius Risser salary is $609,910 per year as Senior Vice President of Bus. Devel. & Portfolio Management and Chief Bus. Officer in MacroGenics, Inc..

How old is Eric Blasius Risser?

Mr. Eric Blasius Risser is 52 years old, born in 1973.

What stocks does Eric Blasius Risser currently own?

As insider, Mr. Eric Blasius Risser owns shares in one company:

Company Title Shares Price per share Total value
MacroGenics, Inc. (MGNX) Senior Vice President of Bus. Devel. & Portfolio Management and Chief Bus. Officer 38,900 $1.51 $58,739

What does MacroGenics, Inc. do?

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX logo
MGNX
MacroGenics, Inc.
$1.51

Eric Blasius Risser insider trading

MacroGenics, Inc.

Mr. Eric Blasius Risser has made 29 insider trades between 2014-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 26,159 units of MGNX stock on 4 Mar 2024. As of 4 Mar 2024 he still owns at least 38,900 units of MGNX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 15,000 $10.15 $152,250
Sale
Common Stock 15,000 $20 $300,000
Sale
Common Stock 26,159 $19.63 $513,501
Option
Employee stock option (right to buy) 15,000 $10.15 $152,250
Option
Restricted Stock Unit 16,670 N/A N/A
Option
Common Stock 16,670 N/A N/A
Option
Employee stock option (right to buy) 8,500 $1.51 $12,835
Option
Common Stock 8,500 $1.51 $12,835
Option
Employee stock option (right to buy) 500 $0.94 $470
Option
Common Stock 500 $0.94 $470
Option
Employee stock option (right to buy) 500 N/A N/A
Option
Common Stock 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Employee stock option (right to buy) 500 N/A N/A
Option
Common Stock 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Sale
Common Stock 1,500 N/A N/A
Option
Employee stock option (right to buy) 1,500 N/A N/A
Option
Common Stock 1,500 N/A N/A
Option
Common Stock 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Employee stock option (right to buy) 500 N/A N/A
Option
Common Stock 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Employee stock option (right to buy) 500 N/A N/A
Sale
Common Stock 1,489 $0.47 $700
Sale
Common Stock 1,489 N/A N/A
Option
Employee stock option (right to buy) 4,489 $1.23 $5,499
Option
Employee stock option (right to buy) 4,489 N/A N/A
Option
Common Stock 4,489 N/A N/A
Option
Common Stock 4,489 $1.23 $5,499
Option
Employee stock option (right to buy) 3,100 N/A N/A
Option
Common Stock 3,100 N/A N/A
Sale
Common Stock 3,100 N/A N/A
Option
Common Stock 500 N/A N/A
Option
Employee stock option (right to buy) 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Common Stock 500 N/A N/A
Option
Employee stock option (right to buy) 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Common Stock 8,032 $1.23 $9,839
Option
Employee stock option (right to buy) 8,032 N/A N/A
Sale
Common Stock 8,032 $15.24 $122,368
Sale
Common Stock 8,032 N/A N/A
Option
Common Stock 8,032 N/A N/A
Option
Employee stock option (right to buy) 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Employee stock option (right to buy) 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Common Stock 500 N/A N/A
Option
Employee stock option (right to buy) 500 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Common Stock 623 N/A N/A
Option
Employee stock option (right to buy) 623 N/A N/A
Sale
Common Stock 623 N/A N/A
Option
Employee stock option (right to buy) 30 N/A N/A
Option
Common Stock 30 N/A N/A
Sale
Common Stock 30 N/A N/A
Option
Stock Option (right to buy) 1,662 N/A N/A
Option
Common Stock 1,662 N/A N/A
Option
Common Stock 1,000 N/A N/A
Option
Stock Option (right to buy) 1,000 N/A N/A
Sale
Common Stock 1,000 N/A N/A
Sale
Common Stock 3,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Employee stock option (right to buy) 3,000 N/A N/A
Option
Employee stock option (right to buy) 2,497 N/A N/A
Option
Common Stock 2,497 N/A N/A
Option
Employee stock option (right to buy) 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Employee stock option (right to buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Common Stock 4,000 N/A N/A
Option
Employee stock option (right to buy) 4,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Employee stock option (right to buy) 3,000 N/A N/A
Sale
Common Stock 1,000 N/A N/A
Option
Employee stock option (right to buy) 1,000 N/A N/A
Option
Common Stock 1,000 N/A N/A
Option
Employee stock option (right to buy) 4,000 N/A N/A
Sale
Common Stock 4,000 N/A N/A
Option
Common Stock 4,000 N/A N/A
Option
Employee stock option (right to buy) 1,000 N/A N/A
Sale
Common Stock 1,000 N/A N/A
Option
Common Stock 1,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Employee stock option (right to buy) 3,000 N/A N/A
Sale
Common Stock 3,000 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Employee stock option (right to buy) 2,000 N/A N/A
Option
Employee stock option (right to buy) 2,000 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Employee Stock Option (right to buy) 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Option
Employee Stock Option (right to buy) 1,500 N/A N/A
Option
Common Stock 1,500 N/A N/A
Option
Common Stock 5,000 $0.94 $4,700
Option
Employee Stock Option (right to buy) 5,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Option (right to buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Option (right to buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Option (right to buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Option (right to buy) 10,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 8,316 N/A N/A
Sale
Common Stock 8,000 N/A N/A
Option
Stock Option (right to buy) 8,000 N/A N/A
Option
Common Stock 8,000 N/A N/A

MacroGenics key executives

MacroGenics, Inc. executives and other stock owners filed with the SEC: